Connect with us

Health

EMA says ‘no new evidence’ to support changes to HRT warnings

SHARE:

Published

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

The European Medicines Agency (EMA) says it has seen no new evidence that points to a need to amend the current labelling of HRT medicines.

On Monday (10 November), the US Department of Health and Human Services (HHS), led by Robert Kennedy, announced that the US medicines regulator, the FDA, would initiate the removal of ‘black box’ warnings from hormone replacement therapies (HRT). Black box warnings are used to indicate that a medication may present serious risks...

To read the rest of this article, click here.

Share this article:

EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.

Trending